Blaschke, Sabine

[["dc.bibliographiccitation.artnumber","45"],["dc.bibliographiccitation.journal","Arthritis Research & Therapy"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Blaschke, Sabine"],["dc.contributor.author","Rinke, Kathinka"],["dc.contributor.author","Maring, Michael"],["dc.contributor.author","Flad, Thomas"],["dc.contributor.author","Patschan, Susann A."],["dc.contributor.author","Jahn, Olaf"],["dc.contributor.author","Mueller, Claudia A."],["dc.contributor.author","Mueller, Georg Anton"],["dc.contributor.author","Dihazi, Hassan"],["dc.date.accessioned","2018-11-07T09:59:46Z"],["dc.date.available","2018-11-07T09:59:46Z"],["dc.date.issued","2015"],["dc.description.abstract","Introduction: The introduction of tumor necrosis factor-alpha (TNF-alpha) antagonists has substantially improved patient's clinical outcome in rheumatoid arthritis (RA). However, nearly 20% to 40% of RA patients do not respond to anti-TNF-alpha treatment strategies. To identify valid predictors of TNF-alpha antagonist response in RA, serum proteome profiles from responders (R) and non-responders (NR) to etanercept, a soluble recombinant TNF-alpha receptor/IgG Fc fusion protein receptor, were compared in a prospective cohort study. Methods: In this clinical study 50 RA patients with inadequate response to conventional DMARDs were included and treated with etanercept. The primary efficacy endpoint was response according to the European League against Rheumatism (EULAR) improvement criteria. Serum samples collected prior to initiation and after six months of etanercept therapy were cleared of the most abundant major proteins by immunoaffinity chromatography. After separation by two-dimensional differential gel electrophoresis (2D-DIGE) and identification by mass spectrometry (MS) data were validated by Western blot analysis. Results: After six months of etanercept treatment 62% (n = 31) of RA patients achieved response. Haptoglobin-alpha 1 (Hp-alpha 1) and -alpha 2 (Hp-alpha 2) and vitamin D-binding protein (VDBP) were found to be significantly upregulated in responder sera (P <= 0.02) at study entry. In contrast, apolipoprotein C-III (ApoC-III) showed significantly higher levels in non-responders (P = 0.0162). At study end ApoA-II, Hp-alpha 1, Hp-alpha 2 and VDBP were identified to be expressed at significantly higher levels (P < 0.05) in responder sera. Conclusions: By application of clinical proteomics in immunodepleted sera we could identify and validate for the first time Hp-alpha 1, -alpha 2, VDBP and ApoC-III as potential biomarkers for prediction of etanercept drug response in RA."],["dc.description.sponsorship","Pfizer Research Initiative"],["dc.identifier.doi","10.1186/s13075-015-0553-1"],["dc.identifier.isi","000352187400001"],["dc.identifier.pmid","25884688"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13467"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37661"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1478-6362"],["dc.relation.issn","1478-6354"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Haptoglobin-alpha 1, -alpha 2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3049"],["dc.bibliographiccitation.issue","14"],["dc.bibliographiccitation.journal","Journal of Clinical Medicine"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Gross, Oliver"],["dc.contributor.author","Moerer, Onnen"],["dc.contributor.author","Rauen, Thomas"],["dc.contributor.author","Böckhaus, Jan"],["dc.contributor.author","Hoxha, Elion"],["dc.contributor.author","Jörres, Achim"],["dc.contributor.author","Kamm, Matthias"],["dc.contributor.author","Elfanish, Amin"],["dc.contributor.author","Windisch, Wolfram"],["dc.contributor.author","Blaschke, Sabine"],["dc.contributor.author","Dreher, Michael"],["dc.contributor.author","Floege, Juergen"],["dc.contributor.author","Kluge, Stefan"],["dc.contributor.author","Schmidt-Lauber, Christian"],["dc.contributor.author","Turner, Jan-Eric"],["dc.contributor.author","Huber, Samuel"],["dc.contributor.author","Addo, Marylyn M."],["dc.contributor.author","Scheithauer, Simone"],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Braun, Gerald S."],["dc.contributor.author","Huber, Tobias B."],["dc.date.accessioned","2021-08-12T07:46:00Z"],["dc.date.available","2021-08-12T07:46:00Z"],["dc.date.issued","2021"],["dc.description.abstract","In COVID-19, guidelines recommend a urinalysis on hospital admission as SARS-CoV-2 renal tropism, post-mortem, was associated with disease severity and mortality. Following the hypothesis from our pilot study, we now validate an algorithm harnessing urinalysis to predict the outcome and the need for ICU resources on admission to hospital. Patients were screened for urinalysis, serum albumin (SA) and antithrombin III activity (AT-III) obtained prospectively on admission. The risk for an unfavorable course was categorized as (1) “low”, (2) “intermediate” or (3) “high”, depending on (1) normal urinalysis, (2) abnormal urinalysis with SA ≥ 2 g/dL and AT-III ≥ 70%, or (3) abnormal urinalysis with SA or AT-III abnormality. Time to ICU admission or death served as the primary endpoint. Among 223 screened patients, 145 were eligible for enrollment, 43 falling into the low, 84 intermediate, and 18 into high-risk categories. An abnormal urinalysis significantly elevated the risk for ICU admission or death (63.7% vs. 27.9%; HR 2.6; 95%-CI 1.4 to 4.9; p = 0.0020) and was 100% in the high-risk group. Having an abnormal urinalysis was associated with mortality, a need for mechanical ventilation, extra-corporeal membrane oxygenation or renal replacement therapy. In conclusion, our data confirm that COVID-19-associated urine abnormalities on admission predict disease aggravation and the need for ICU (ClinicalTrials.gov number NCT04347824)."],["dc.description.abstract","In COVID-19, guidelines recommend a urinalysis on hospital admission as SARS-CoV-2 renal tropism, post-mortem, was associated with disease severity and mortality. Following the hypothesis from our pilot study, we now validate an algorithm harnessing urinalysis to predict the outcome and the need for ICU resources on admission to hospital. Patients were screened for urinalysis, serum albumin (SA) and antithrombin III activity (AT-III) obtained prospectively on admission. The risk for an unfavorable course was categorized as (1) “low”, (2) “intermediate” or (3) “high”, depending on (1) normal urinalysis, (2) abnormal urinalysis with SA ≥ 2 g/dL and AT-III ≥ 70%, or (3) abnormal urinalysis with SA or AT-III abnormality. Time to ICU admission or death served as the primary endpoint. Among 223 screened patients, 145 were eligible for enrollment, 43 falling into the low, 84 intermediate, and 18 into high-risk categories. An abnormal urinalysis significantly elevated the risk for ICU admission or death (63.7% vs. 27.9%; HR 2.6; 95%-CI 1.4 to 4.9; p = 0.0020) and was 100% in the high-risk group. Having an abnormal urinalysis was associated with mortality, a need for mechanical ventilation, extra-corporeal membrane oxygenation or renal replacement therapy. In conclusion, our data confirm that COVID-19-associated urine abnormalities on admission predict disease aggravation and the need for ICU (ClinicalTrials.gov number NCT04347824)."],["dc.description.sponsorship","Deutsche Forschungsgemeinschaft"],["dc.description.sponsorship","Bundesministerium für Bildung und Forschung"],["dc.identifier.doi","10.3390/jcm10143049"],["dc.identifier.pii","jcm10143049"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/88595"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-448"],["dc.publisher","MDPI"],["dc.relation.eissn","2077-0383"],["dc.rights","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Validation of a Prospective Urinalysis-Based Prediction Model for ICU Resources and Outcome of COVID-19 Disease: A Multicenter Cohort Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","131"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Histochemistry and Cell Biology"],["dc.bibliographiccitation.lastpage","144"],["dc.bibliographiccitation.volume","136"],["dc.contributor.author","Batusic, Danko S."],["dc.contributor.author","von Bargen, Alexander"],["dc.contributor.author","Blaschke, Sabine"],["dc.contributor.author","Dudas, Jozsef"],["dc.contributor.author","Ramadori, Giuliano"],["dc.date.accessioned","2018-11-07T08:53:41Z"],["dc.date.available","2018-11-07T08:53:41Z"],["dc.date.issued","2011"],["dc.description.abstract","Liver regeneration may take place after liver injury through replication of hepatocytes or hepatic progenitor cells called oval cells. Interferons (IFN) are natural cytokines with pleiotrophic effects including antiviral and antiproliferative actions. No data are yet available on the physiology and cellular source of natural IFNs during liver regeneration. To address this issue, we have analyzed the levels and biologic activities of IFN-alpha/IFN-gamma in two models of partial hepatectomy. After 2/3rd partial hepatectomy (PH), hepatic levels of IFN-alpha and IFN-gamma declined transiently in contrast to a transient increase of the IFN-gamma serum level. After administration of 2-acetylaminofluorene and partial hepatectomy (AAF/PH model), however, both IFN-alpha and IFN-gamma expression were up-regulated in regenerating livers. Again, the IFN-gamma serum level was transiently increased. Whereas hepatic IFN-gamma was up-regulated early (day 1-5), but not significantly, in the AAF/PH model, IFN-alpha was significantly up-regulated at later time points in parallel to the peak of oval cell proliferation (days 7-9). Biological activity of IFN-alpha was shown by activation of IFN-alpha-specific signal transduction and induction of IFN-alpha specific-gene expression. We found a significant infiltration of the liver with inflammatory monocyte-like mononuclear phagocytes (MNP) concomitant to the frequency of oval cells. We localized IFN-alpha production only in MNPs, but not in oval cells. These events were not observed in normal liver regeneration after standard PH. We conclude that IFN-gamma functions as an acute-phase cytokine in both models of liver regeneration and may constitute a systemic component of liver regeneration. IFN-alpha was increased only in the AAF/PH model, and was associated with proliferation of oval cells. However, oval cells seem not to be the source of IFN-alpha. Instead, inflammatory MNP infiltrating AAF/PH-treated livers produce IFN-alpha. These inflammatory MNPs may be involved in the regulation of the oval cell compartment through local expression of cytokines, including IFN-alpha."],["dc.description.sponsorship","Deutsche Forschungsgemeinschaft [SFB 402, D3]"],["dc.identifier.doi","10.1007/s00418-011-0838-7"],["dc.identifier.isi","000293638800002"],["dc.identifier.pmid","21822998"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/7129"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/22478"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0948-6143"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Different physiology of interferon-alpha/-gamma in models of liver regeneration in the rat"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1312"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Intensive Care Medicine"],["dc.bibliographiccitation.lastpage","1313"],["dc.bibliographiccitation.volume","35"],["dc.contributor.author","Hagenah, Gerrit C."],["dc.contributor.author","Klinger, Michael"],["dc.contributor.author","Nagorsnik, Ulf"],["dc.contributor.author","Puls, Miriam"],["dc.contributor.author","Schweyer, Stefan"],["dc.contributor.author","Mueller, Georg Anton"],["dc.contributor.author","Blaschke, Sabine"],["dc.date.accessioned","2018-11-07T08:28:11Z"],["dc.date.available","2018-11-07T08:28:11Z"],["dc.date.issued","2009"],["dc.identifier.doi","10.1007/s00134-009-1398-3"],["dc.identifier.isi","000267220800027"],["dc.identifier.pmid","19169669"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?goescholar/3478"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/16365"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0342-4642"],["dc.relation.orgunit","Wirtschaftswissenschaftliche Fakultät"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Acute renal failure due to severe rhabdomyolysis: a rare clinical manifestation of atrial myxoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1320"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Drug Testing and Analysis"],["dc.bibliographiccitation.lastpage","1335"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Grapp, Marcel"],["dc.contributor.author","Kaufmann, Christoph"],["dc.contributor.author","Schwelm, Hannes M."],["dc.contributor.author","Neukamm, Merja A."],["dc.contributor.author","Blaschke, Sabine"],["dc.contributor.author","Eidizadeh, Abass"],["dc.date.accessioned","2021-04-14T08:26:18Z"],["dc.date.available","2021-04-14T08:26:18Z"],["dc.date.issued","2020"],["dc.description.abstract","Abstract Among the increasing number of new psychoactive substances, 3′,4′‐methylenedioxy‐α‐pyrrolidinohexanophenone (MDPHP) belongs to the group of synthetic cathinones, which are the derivatives of the naturally occurring compound cathinone, the main psychoactive ingredient in the khat plant. Currently, only limited data are available for MDPHP, and no information is available on its human metabolism. We describe the toxicological investigation of nine cases associated with the use of MDPHP during the period February–June 2019. Serum MDPHP concentrations showed a high variability ranging from 3.3 to 140 ng/mL (mean 30.3 ng/mL and median 16 ng/mL). Intoxication symptoms of the described cases could not be explained by the abuse of MDPHP alone because in all cases the co‐consumption of other psychotropic drugs with frequent occurrence of opiates and benzodiazepines could be verified. Therefore, the patients showed different clinical symptoms, including aggressive behaviour, delayed physical response, loss of consciousness and coma. Liquid chromatography–high‐resolution mass spectrometry was successfully used to investigate the human in vivo metabolism of MDPHP using authentic human urine samples. The metabolism data for MDPHP were further substantiated by the analysis of human urine using gas chromatography–mass spectrometry (GC–MS, a widely used systematic toxicological analysis method appropriate for the toxicological detection of MDPHP intake), which revealed the presence of seven phase I metabolites and three phase II metabolites as glucuronides. GC‐MS spectral data for MDPHP and metabolites are provided. The identified metabolite pattern corroborates the principal metabolic pathways of α‐pyrrolidinophenones in humans."],["dc.description.abstract","In this study, we describe the toxicological investigation of nine cases associated with the use of the novel designer stimulant MDPHP. Serum concentrations, analytically confirmed co‐consumption, and intoxication symptoms are discussed. High‐resolution mass spectrometry and gas chromatography–mass spectrometry was successfully used to investigate the human in vivo metabolism of MDPHP using authentic human urine samples. The identified metabolite pattern, including seven phase I metabolites and three glucuronides, corroborates the principal metabolic pathways of α‐pyrrolidinophenones in humans. image"],["dc.identifier.doi","10.1002/dta.2869"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81897"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1942-7611"],["dc.relation.issn","1942-7603"],["dc.rights","This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited."],["dc.title","Intoxication cases associated with the novel designer drug 3′,4′‐methylenedioxy‐α‐pyrrolidinohexanophenone and studies on its human metabolism using high‐resolution mass spectrometry"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","78"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Diagnostics"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Dörschug, Anja"],["dc.contributor.author","Schwanbeck, Julian"],["dc.contributor.author","Hahn, Andreas"],["dc.contributor.author","Hillebrecht, Anke"],["dc.contributor.author","Blaschke, Sabine"],["dc.contributor.author","Mese, Kemal"],["dc.contributor.author","Groß, Uwe"],["dc.contributor.author","Dierks, Sascha"],["dc.contributor.author","Frickmann, Hagen"],["dc.contributor.author","Zautner, Andreas E."],["dc.date.accessioned","2021-04-14T08:29:44Z"],["dc.date.available","2021-04-14T08:29:44Z"],["dc.date.issued","2021"],["dc.description.sponsorship","Open-Access-Publikationsfonds 2021"],["dc.identifier.doi","10.3390/diagnostics11010078"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82978"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","2075-4418"],["dc.relation.orgunit","Institut für Medizinische Mikrobiologie"],["dc.rights","CC BY 4.0"],["dc.title","Comparison of Five Serological Assays for the Detection of SARS-CoV-2 Antibodies"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","458"],["dc.bibliographiccitation.issue","4-5"],["dc.bibliographiccitation.journal","Kidney and Blood Pressure Research"],["dc.bibliographiccitation.lastpage","463"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Gade, Katrin"],["dc.contributor.author","Blaschke, Sabine"],["dc.contributor.author","Rodenbeck, Andrea"],["dc.contributor.author","Becker, Andreas"],["dc.contributor.author","Anderson-Schmidt, Heike"],["dc.contributor.author","Cohrs, Stefan"],["dc.date.accessioned","2018-11-07T09:29:28Z"],["dc.date.available","2018-11-07T09:29:28Z"],["dc.date.issued","2013"],["dc.description.abstract","Background: The aetiology of uremic restless legs syndrome (RLS) remains unclear. Our research investigated whether an elevated plasma concentration of the excitatory amino acid homocysteine might be associated with RLS occurrence in patients with chronic renal insufficiency on hemodialysis. Methods: Total plasma homocysteine as well as creatinine, urea, folate, parathyroid hormone, hemoglobin, iron, ferritin, phosphate, calcium, magnesium, and albumin levels were compared between 26 RLS-affected (RLSpos) and 26 non-affected (RLSneg) patients on chronic hemodialysis. We further compared subjective sleep quality between RLSpos and RLSneg patients using the Pittsburgh-Sleep-Quality-Index and investigated possible relationships between laboratory parameters and sleep quality. Results: Taking individual albumin concentrations into account, a significant positive correlation between total plasma homocysteine and RLS occurrence was observed (r= 0.246; p=0.045). Sleep quality was significantly more reduced in RLSpos compared to RLSneg patients and RLS severity correlated positively with impairment of sleep quality. Bad sleep quality in all patients was associated with higher concentrations of parathyroid hormone. Conclusion: Our results suggest a possible aetiological role of homocysteine in uremic RLS. They confirm that uremic RLS is an important factor causing sleep impairment in patients on hemodialysis. Higher parathyroid hormone levels might also be associated with bad sleep quality in these patients. Copyright (C) 2013 S. Karger AG, Basel"],["dc.identifier.doi","10.1159/000355727"],["dc.identifier.isi","000328196500024"],["dc.identifier.pmid","24247595"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10747"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/31040"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.relation.issn","1423-0143"],["dc.relation.issn","1420-4096"],["dc.rights","CC BY-NC 3.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/3.0"],["dc.title","Uremic Restless Legs Syndrome (RLS) and Sleep Quality in Patients With End-Stage Renal Disease on Hemodialysis: Potential Role of Homocysteine and Parathyroid Hormone"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","440"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","European Journal of Immunology"],["dc.bibliographiccitation.lastpage","445"],["dc.bibliographiccitation.volume","46"],["dc.contributor.author","Schminke, Boris"],["dc.contributor.author","Trautmann, Sandra"],["dc.contributor.author","Mai, Burkhard"],["dc.contributor.author","Miosge, Nicolai"],["dc.contributor.author","Blaschke, Sabine"],["dc.date.accessioned","2018-08-20T12:24:05Z"],["dc.date.available","2018-08-20T12:24:05Z"],["dc.date.issued","2016"],["dc.description.abstract","Mesenchymal stem cells are known to exert immunomodulatory effects in inflammatory diseases. Immuneregulatory cells lead to progressive joint destruction in rheumatoid arthritis (RA). Proinflammatory cytokines, such as tumour necrosis factor α (TNF-α) and interleukins (ILs) are the main players. Here, we studied progenitor cells from RA cartilage (RA-CPCs) that are positive for IL-17 receptors to determinate the effects of inflammation on their chondrogenic potenial. IL-17A/F reduced the chondrogenic potential of these cells via the upregulation of RUNX2 protein and enhanced IL-6 protein and MMP3 mRNA levels. Blocking antibodies against IL-17 positively influenced their repair potential. Furthermore, treating the RA-CPCs with the anti-human IL-17 antibody secukinumab or the anti-TNF-α antibody adalimumab reduced the proinflammatory IL-6 protein level and positively influenced the secretion of anti-inflammatory IL-10 protein. Additionally, adalimumab and secukinumab in particular reduced RUNX2 protein to promote chondrogenesis. The amelioration of inflammation, particularly via IL-17 antagonism, might be a new therapeutic approach for enhancing intrinsic cartilage repair mechanisms in RA patients."],["dc.identifier.doi","10.1002/eji.201545910"],["dc.identifier.pmid","26558442"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14042"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/15432"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","final"],["dc.relation.eissn","1521-4141"],["dc.relation.eissn","0014-2980"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.title","Interleukin 17 inhibits progenitor cells in rheumatoid arthritis cartilage"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","International Journal of Nephrology"],["dc.bibliographiccitation.lastpage","12"],["dc.bibliographiccitation.volume","2012"],["dc.contributor.author","Patschan, Susann"],["dc.contributor.author","Patschan, Daniel"],["dc.contributor.author","Henze, Elvira"],["dc.contributor.author","Blaschke, Sabine"],["dc.contributor.author","Wessels, Johannes T."],["dc.contributor.author","Müller, Gerhard Anton"],["dc.date.accessioned","2019-07-09T11:53:33Z"],["dc.date.available","2019-07-09T11:53:33Z"],["dc.date.issued","2012"],["dc.description.abstract","Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are autoimmune-mediated diseases characterized by vasculitic inflammation of respiratory tract and kidneys. Clinical observations indicated a strong association between disease activity and serumlevels of certain types of autoantibodies (antineutrophil cytoplasm antibodies with cytoplasmic [cANCA in GPA] or perinuclear [pAN CA in MPA] immunofluorescence). Pathologically, both diseases are characterized by severe microvascular endothelial cell damage. Early endothelial outgrowth cells (eEOCs) have been shown to be critically involved in neovascularization under both physiological and pathological condition. Objectives. The principal aims of our study were (i) to analyze the regenerative activity of the eEOC system and (ii) to determine mPR3 and MPO expression in myelo monocytic cells with endothelial characteristics in GPA and MPA patients. Methods. In 27 GPA and 10 MPA patients, regenerative activity bloodderived eEOCs were analyzed using a culture-forming assay. Flk-1+, CD133+/Flk-1+, mPR3+, and Flk-1+/mPR3+ myelomonocytic cells were quantified by FACS analysis. Serum levels of Angiopoietin-1 and TNF-α were measured by ELISA. Results. We found reduced eEOC regeneration, accompanied by lower serum levels of Angiopoietin-1 in GPA patients as compared to healthy controls. In addition, the total numbers of Flk-1+ myelomonocytic cells in the peripheral circulation were decreased. Membrane PR3 expression was significantly higher in total as well as in Flk-1+ myelomonocytic cells. Expression of MPO was not different between the groups. Conclusions. These data suggest impairment of the eEOC system and a possible role for PR3 in this process in patients suffering from GPA."],["dc.identifier.doi","10.1155/2012/715049"],["dc.identifier.fs","592925"],["dc.identifier.pmid","22792461"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/7718"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60445"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Impairment and Differential Expression of PR3 and MPO on Peripheral Myelomonocytic Cells with Endothelial Properties in Granulomatosis with Polyangiitis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1442"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","PROTEOMICS"],["dc.bibliographiccitation.lastpage","1450"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Sparbier, Katrin"],["dc.contributor.author","Wenzel, Thomas"],["dc.contributor.author","Dihazi, Hassan"],["dc.contributor.author","Blaschke, Sabine"],["dc.contributor.author","Mueller, Gerhard-Anton"],["dc.contributor.author","Deelder, Andre"],["dc.contributor.author","Flad, Thomas"],["dc.contributor.author","Kostrzewa, Markus"],["dc.date.accessioned","2018-11-07T08:32:28Z"],["dc.date.available","2018-11-07T08:32:28Z"],["dc.date.issued","2009"],["dc.description.abstract","The discovery of novel biomarkers by means of advanced detection tools based on proteomic analysis technologies necessitates the development of improved diagnostic methods for application in clinical routine. On the basis of three different application examples, this review presents the limitations of conventional routine diagnostic assays and illustrates the advantages of immunoaffinity enrichment combined with MALDI-TOF MS. Applying this approach increases the specificity of the analysis supporting a better diagnostic recognition, sensitivity, and differentiation of certain diseases. The use of MALDI-TOF MS as detection method facilitates the identification of modified peptides and proteins providing additional information. Further, employing respective internal standard peptides allows for relative and absolute quantitation which is mandatory in the clinical context. Although MALDI-TOF MS is not yet established for clinical routine diagnostics this technology has a high potential for improvement of clinical diagnostics and monitoring therapeutic efficacy."],["dc.description.sponsorship","BMBF [0313684B]"],["dc.identifier.doi","10.1002/pmic.200800616"],["dc.identifier.isi","000264890400004"],["dc.identifier.pmid","19235164"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6185"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/17349"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-v C H Verlag Gmbh"],["dc.relation.issn","1615-9853"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Immuno-MALDI-TOF MS: New perspectives for clinical applications of mass spectrometry"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]